'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 17.90% to Rs 949.42 crore. Operating profit margin has jumped from 27.08% to 30.75%, leading to 33.87% rise in operating profit to Rs 291.92 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 12.26% to 11.44%. Purchase of finished goods cost fell from 21.91% to 19.28%. Employee cost decreased from 19.05% to 14.64%. Other expenses rose from 17.39% to 20.38%.
Other income rose 24.76% to Rs 35.07 crore. PBIDT rose 32.83% to Rs 326.99 crore. Provision for interest fell 71.88% to Rs 0.09 crore.
PBDT rose 32.97% to Rs 326.9 crore. Provision for depreciation rose 9.88% to Rs 18.8 crore.
Profit before ...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
(15-Feb-2025)
ITL Industries
Net up 10% on higher sales
|
|